[1]
Lebwohl, M., Kircik, L. , Moore, A., Stein Gold, L., Del Rosso, J., Draelos, Z., Gooderham, M., Green, L., Herbert, A., Papp, K., Bagel, J. , Bhatia, N., Ferris, L., Jones, T. , Kempers, S., Pariser, D., Yamauchi, P., Zirwas, M., Feng, A. , Burnett, P., Higham, R. and Berk, D. 2021. Once-Daily Roflumilast Cream 0.3%, a Potent Phosphodiesterase-4 Inhibitor, Provided Safe and Effective Treatment of Psoriasis in the DERMIS-1 and DERMIS-2 Phase 3 Trials. SKIN The Journal of Cutaneous Medicine. 5, 6 (Nov. 2021), s42. DOI:https://doi.org/10.25251/skin.5.supp.42.